Enzene Biosciences to Expand into New Jersey, Investing $50 Million in Bio Manufacturing Plant
Introduction:
Enzene Biosciences, a global biotech company headquartered in India, has announced plans to establish its first manufacturing plant in New Jersey.
Features:
The state-of-the-art biopharmaceutical manufacturing facility is expected to commence operations in June 2024.
Enzene Biosciences, a subsidiary of Alkem Laboratories Ltd., is a Contract Development and Manufacturing Organization (CDMO) that offers services to pharmaceutical companies worldwide.
As part of its expansion, Enzene Biosciences intends to initially hire 50 employees and aims to eventually employ 300 individuals at the New Jersey facility.
New Jersey's favorable business environment, skilled workforce, strategic location, supportive growth ecosystem, and cultural ties have been key factors in attracting Indian companies like Enzene Biosciences.
Enzene Biosciences' expansion into New Jersey will benefit from the state's highly skilled workforce, advanced infrastructure, renowned academic institutions, and collaborative life sciences community.
The strategic expansion to New Jersey demonstrates Alkem Laboratories Ltd.'s commitment to investing in Biologics CDMO and positions Enzene Biosciences for future growth and partnerships.
New Jersey's business-friendly environment provides a conducive atmosphere for investment and growth in the biopharmaceutical sector, making it an ideal location for Enzene Biosciences' long-term viability and success.
The expansion of Enzene Biosciences in New Jersey showcases the state's global presence and expertise in the biopharmaceutical industry, covering areas such as clinical trials and large-scale manufacturing.
Specifications:
Name: Enzene Biosciences
Type: Expansion
